Alternatives · ranked by WeighScore
Alternatives to AquaVita NextGen
AquaVita NextGen grades C (56.3/100), #456 of 544 on our scorecard. Here are the other providers we've graded on the same six dimensions — ranked by WeighScore, highest first.
You're comparing against
AquaVita NextGen →Our top-graded alternative
CoreAge Rx leads the full scorecard.
Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
More alternatives, ranked
Prints its whole term ladder before intake and then headlines the cheapest rung of it: the advertised $199 is a twelve-month plan charged as one $2,388 payment, and month-to-month is $349.
FDAWarning letter issued to Lean Rx, Inc. dba SkinnyRx in February 2026. See the FDA warning-letter database.
TeleDocs360 is a cash-pay telehealth service offering compounded GLP-1 weight loss medications, including injectable semaglutide and tirzepatide, oral semaglutide, plus phentermine and NAD+ therapy.
Dr. Arevitalize (Dr.Arevitalize Health, Inc.) is a LegitScript-certified telehealth platform offering compounded GLP-1 weight-loss medication in both injectable and oral-capsule forms — semaglutide from $269/mo and tirzepatide from $349/mo, sold in 1-, 3-, 6-, and 12-month bundles.
Apex MD is a US virtual telemedicine platform licensed in all 50 states that prescribes compounded GLP-1 medications for weight loss.
TeleCareSpot is a telehealth weight-loss platform offering doctor-prescribed compounded GLP-1s with flat, all-inclusive monthly pricing: compounded semaglutide at $299/month and tirzepatide at $399/month (all doses), plus oral tirzepatide and phentermine.
The 6 above are the closest matches to AquaVita NextGen on the WeighScore. Every provider we grade — all 544 of them — is scored on the same six factors: browse every graded provider.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.